2015-08-06T17:20:13-05:00 2015-03-31 910189318 MOSS ADAMS LLP 4747 EXECUTIVE DRIVE SUITE 1300 SAN DIEGO CA 92121 990 2014-04-01 954002032 ALFRED E MANN FOUNDATION FOR SCIENTIFIC RESEARCH ALFR 6617026700 25134 RYE CANYON LOOP SANTA CLARITA CA 91355 DAVID HANKIN CEO 6617026700 2015-08-04 1 PATRICIA J MAYER P00188643 8586271400 2014 2016-04-25 22:37:26Z DAVID HANKIN 25134 RYE CANYON LOOP SANTA CLARITA CA 91355 164295834 0 X WWW.AEMF.ORG X 1985 CA CONDUCT MEDICAL AND SCIENTIFIC RESEARCH 4 4 102 6 514120 52585 825894 101479 2525491 1859751 12263895 5583714 4024562 49760 19639842 7594704 10500 19000 0 0 10944389 10585260 0 0 135219 13248290 7298385 24203179 17902645 -4563337 -10307941 114740000 108633540 11197787 15219334 103542213 93414206 X THE ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH IS A MEDICAL RESEARCH ORGANIZATION DEDICATED TO DEVELOPING AND COMMERCIALIZING INNOVATIVE SOLUTIONS FOR SIGNIFICANT UNMET MEDICAL CONDITIONS. 0 0 6842024 19000 506653 IMPLANTABLE MYOELECTRIC SENSOR (IMES I + CLINICAL):INITIALLY, THE "IMES" PROJECT WAS A CONSORTIUM PROJECT WITH THE FOLLOWING PARTNERS: NORTHWESTERN UNIVERSITY, THE ILLINOIS INSTITUTE OF TECHNOLOGY, AND SIGENICS (A CLOSELY HELD ENGINEERING COMPANY). THE INITIAL FUNDING FOR THE IMES PROGRAM WAS COMING FROM THE NATIONAL INSTITUTES FOR BIOMEDICAL IMAGING AND BIOENGINEERING (NIBIB) AND THE NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT (NICHD), AS WELL AS, THE DEFENSE ADVANCED RESEARCH PROJECTS AGENCY (DARPA). IN 2008, AMF ASSUMED CONTROL AND RESPONSIBILITY FOR THE ENTIRE PROJECT, PERFORMING MISSION CRITICAL ENGINEERING TASKS AND PREPARING FOR AND CONDUCTING A CLINICAL TRIAL. THE IMES SYSTEM IMPLANTED IN THE RESIDUAL LIMB OF A LIMB AMPUTEE WOULD TRANSMIT MUSCLE SIGNALS TO THE WEARABLE PROSTHESIS TO PERMIT CONTROL OF THE PROSTHESIS IN A MORE NATURAL AND INTUITIVE MANNER. STATUS:AMF HAS QUALIFIED THE FIRST GENERATION IMES SYSTEM FOR A CLINICAL TRIAL WITH UPPER LIMB AMPUTEES. A CLINICAL TRIAL PROTOCOL WAS DEVELOPED AND FDA APPROVAL WAS OBTAINED. THREE PATIENTS HAVE BEEN IMPLANTED AT WALTER REED NATIONAL MILITARY MEDICAL CENTER ("WALTER REED") AND HAVE REPORTED THAT THE NEW EQUIPMENT MADE AVAILABLE TO THEM DURING THE STUDY HAS IMPROVED THEIR QUALITY OF LIFE. AMF SUPPORTS THIS CLINICAL TRIAL DIRECTLY WITH FREQUENT ON-SITE VISITS BY AMF PERSONNEL, WHO WORK IN CONJUNCTION WITH PHYSICIANS AND OTHER CAREGIVERS AT WALTER REED. AMF ALSO HAS TWO GRANT APPLICATIONS PENDING TO FUND ADDITIONAL CLINICAL STUDIES AT WALTER REED WHICH WILL INVOLVE LOWER LIMB AMPUTEES AND TRANSHUMERAL AMPUTEES. DURING 2014 AMF ALSO CONTINUED SUPPORTING A COLLABORATION WITH OSSUR, A MAKER OF LOWER-LIMB PROSTHETICS AND OTHER ORTHOTIC DEVICES, WHERE TWO LOWER LIMB AMPUTEE/PATIENTS WERE IMPLANTED WITH IMES DEVICES. ADDITIONALLY, AMF ENTERED INTO A COLLABORATION AGREEMENT WITH OTTOBOCK, THE WORLD'S LARGEST MAKER OF PROSTHETIC DEVICES (BOTH UPPER AND LOWER LIMB), TO EVALUATE IMES DEVICES IN CONNECTION WITH A TRANSHUMERAL (UPPER LIMB) AMPUTEE, WHERE THREE PATIENTS WERE IMPLANTED WITH IMES. THE OSSUR STUDY IS BEING CONDUCTED IN ICELAND, AND THE OTTOBOCK STUDY IS BEING CONDUCTED IN AUSTRIA, AT EUROPE'S LARGEST HOSPITAL, VIENNA GENERAL HOSPITAL, UNDER THE AUSPICES OF DR. OSKAR ASZMANN OF THE CHRISTIAN DOPPLER LABORATORY FOR RESTORATION OF EXTREMITY FUNCTION, MEDICAL UNIVERSITY OF VIENNA. 3532973 0 26010 ADVANCED TECHNOLOGY PROJECTS: THE TEAM IS COMPRISED OF RESEARCH SCIENTISTS, ENGINEERS, LEGAL AND INTELLECTUAL PROPERTY EXPERTS, BUSINESS STRATEGISTS AND ANALYSTS WHO MONITOR AND EVALUATE NEW TECHNOLOGIES AND NEW PROJECT IDEAS AND CONCEPTS BEFORE THEY ARE ELEVATED TO THE STATUS OF FULL-FLEDGED DEVELOPMENT PROGRAMS. THE GROUP ALSO PROVIDES BUSINESS PLANNING SUPPORT FOR MORE MATURE AMF PROGRAMS THAT ARE ON THEIR WAY TO BEING COMMERCIALIZED. AMF HAS SEVERAL RESEARCH AND DEVELOPMENT EFFORTS UNDER WAY IN THIS GROUP THAT ARE DIRECTED AT DEVELOPING ADVANCED TECHNOLOGIES AND CONCEPTS, INCLUDING INNOVATIVE USES FOR PRESSURE SENSORS TO PROVIDE FEEDBACK FOR ROBOTIC PROSTHETIC LIMBS, NOVEL PACKAGING AND MANUFACTURING PROCESSES FOR IMPLANTABLE DEVICES, AND IMPLANTABLE PUMPS AND SENSORS. STATUS:AS THE PROJECTS ARE IN INITIAL FEASIBILITY OR PROOF-OF-CONCEPT STAGE FOR THE MOST PART, EXPENDITURES ON ANY INDIVIDUAL PROJECT ARE LIMITED. SUCCESSFUL PROJECTS ARE SCREENED FOR ELEVATION TO DEVELOPMENT PROGRAM STATUS, OR TO BE FINANCED IN SPINOUT COMPANIES BY THIRD PARTIES. UNSUCCESSFUL EFFORTS ARE TERMINATED. DURING THE PREVIOUS PERIOD A NUMBER OF NEW INNOVATIVE PROJECTS HAVE BEEN EVALUATED BY THE TEAM. SEVERAL NEW AND PROMISING AREAS WERE EVALUATED AND ONE OR MORE WILL BECOME FORMAL PROJECTS IN 2015. 2996319 0 573686 IMPLANTABLE MYOELECTRIC SENSOR II (IMES II):THE INITIAL COLLABORATION WAS RE-VITALIZED TO COMMENCE RESEARCH AND DEVELOPMENT WORK ON A SECOND GENERATION OF IMES, (PARTIALLY SUPPORTED BY A GRANT FROM THE NATIONAL INSTITUTES OF HEALTH) WHICH WILL CONTAIN ADVANCED FEATURES TO IMPROVE MEDICAL OUTCOMES AT NO ADDITIONAL COST TO THE PATIENT OR HEALTHCARE SYSTEM. INITIAL DESIGN IS COMPLETE WITH MAJOR FOCUS BEING ON THE DEVELOPMENT OF A CUSTOM INTEGRATED CIRCUIT.STATUS: THE FINAL DESIGN OF THE CUSTOM INTEGRATED CIRCUIT IS COMPLETE AND IS UNDERGOING FABRICATION. PERIPHERAL DEVICES THAT INCLUDE A TELEMETRY CONTROLLER MODULE THAT RELAYS MUSCLE SIGNALS TO THE PROSTHETIC, AND A CLINICIAN PROGRAMMER HAVE PASSED THE FIRST DESIGN REVIEW. PRODUCTION TEST SYSTEMS ARE BEING CONSTRUCTED TO PREPARE FOR FINAL SYSTEM VERIFICATION AND VALIDATION. PRODUCT QUALIFICATION IS PLANNED FOR CALENDAR YEAR 2016. 1089299 0 779412 LEADED IMPLANTABLE MYOELECTRIC SENSOR (LIMES):AMF HAS RECEIVED FUNDING FROM DARPA TO DEVELOP A DERIVATIVE VERSION OF THE IMES DEVICE, BY ATTACHING A LEAD TO THE IMES CAPSULE. THE LEAD SIGNIFICANTLY EXTENDS THE BENEFITS OF IMES, PARTICULARLY WHEN THE TARGETED RESIDUAL MUSCLE IS OF INSUFFICIENT SIZE TO SUPPORT THE IMPLANTATION OF THE CAPSULE. THIS PROJECT WILL QUALIFY BIPOLAR LEAD ATTACHMENT PROCESSES AND SATISFY TECHNICAL REQUIREMENTS FOR INTENDED USE IN HUMANS. STATUS: THE PROJECT IS ON SCHEDULE FOR COMPLETION IN 2015 WITH MAJOR ACTIVITIES COMPLETED IN 2014, INCLUDING THE PRODUCTION BUILD AND INITIAL QUALIFICATION TESTING OF THE IMPLANT. DESIGN, DEVELOPMENT, AND FINAL TESTING WERE COMPLETED WITH THE FINAL REPORTS PREPARED. MANUFACTURING DOCUMENTATION IS COMPLETE AND PRODUCT CAN BE BUILT AS NEEDED (EXPENSES OF $989,876).SLEEP APNEA:AS PART OF ADVANCED TECHNOLOGY RESEARCH, AMF IS INVESTIGATING THE NEED FOR NEWER METHODS TO TREAT OBSTRUCTED SLEEP APNEA (OSA). OSA IS A POORLY TREATED MEDICAL CONDITION WHERE CURRENT TREATMENT OPTIONS ARE POORLY ADOPTED AND WHEN ADOPTED, HAVE SIGNIFICANTLY POOR COMPLIANCE RATES. THE AIM OF THE AMF PROGRAM IS TO DETERMINE IF NEUROSTIMULATION CAN IMPROVE MEDICAL OUTCOMES AT A LOWER COST THAN CURRENTLY AVAILABLE TREATMENT OPTIONS. SUCH A DEVICE WOULD BE FULLY IMPLANTED WITH SEAMLESS OPERATION REQUIRING MINIMAL INTERACTION FROM A PATIENT, THEREBY OFFERING A LEVEL OF COMPLIANCE AND EFFICACY FAVORABLE TO GOLD STANDARD TREATMENTS, BUT DELIVERING SUPERIOR HEALTHCARE OUTCOMES RESULTING FROM CONSISTENT ADHERENCE. STATUS:A COMPREHENSIVE HEALTHCARE ECONOMIC ANALYSIS WAS PERFORMED THIS YEAR DEMONSTRATING A NEED FOR A TOLERABLE TREATMENT. THE PERFORMANCES OF IMPLANTED TECHNOLOGIES ARE BEING EVALUATED THIS YEAR (EXPENSES OF $71,955).RADIO FREQUENCY MICROSTIMULATOR (RFM):RFM IS A SYSTEM OF DEVICES INTENDED TO STIMULATE NERVES TO CONTROL MUSCLE MOVEMENT IN PATIENTS WHO HAVE EXPERIENCED A DEBILITATING MUSCLE/NERVE INJURY OR DISEASE. THE SYSTEM CONSISTS OF IMPLANTED MICROSTIMULATORS, SURGICAL TOOLS USED TO IMPLANT THE MICROSTIMULATORS, EXTERNAL COMPONENTS USED TO POWER THE IMPLANTED MICROSTIMULATORS (A CONTROL UNIT AND RF COIL), AND A LAPTOP WITH CUSTOM SOFTWARE USED TO PROGRAM THE MICROSTIMULATORS. STATUS:AFTER RECEIVING IDE APPROVAL FROM THE FDA ON JUNE 4, 2012 FOR A CLINICAL STUDY FOR IMPROVEMENT OF ARM FUNCTIONS FOLLOWING TRAUMATIC BRAIN INJURY, AMF HAS COMPLETED THE SINGLE PATIENT TRIAL AND HAS CLOSED THE STUDY. PATIENT RESULTS WERE WITHIN THE EXPECTED RANGE (EXPENSES OF $18,755).FUNCTION ELECTRICAL BATTERY POWERED MICROSTIMULATOR (FEBPM):THE FEBPM PROGRAM (FORMERLY THE BATTERY POWERED MICROSTIMULATOR (BPM) PROGRAM) IS THE DEVELOPMENT OF THE NEXT-GENERATION MICROSTIMULATOR SYSTEM. IT IS DESIGNED FOR A WIDE RANGE OF MEDICAL APPLICATIONS INCLUDING LOCALIZED INDIVIDUAL MUSCLE CONTROL AND ORCHESTRATED MUSCLE GROUP CONTROL. THE PRESENT MICROSTIMULATOR (RFM - SEE ABOVE) IS POWERED AND CONTROLLED THROUGH AN EXTERNAL RF FIELD AND ONLY A FEW MICROSTIMULATORS CAN BE CONTROLLED AT ONCE USING A CONTROL ALGORITHM INSTALLED ON A PC AND UTILIZING LIMITED ACTIVITY SEQUENCES. BY CONTRAST, THE FEBPM IMPLANT HAS ITS OWN POWER SUPPLY WHICH CAN BE RECHARGED AS NEEDED AND THEN CAN OPERATE FOR PERIODS OF TIME. NUMEROUS FEBPM'S CAN BE COMMUNICATED WITH AND CONTROLLED USING ONE EXTERNAL CONTROLLER. FUTURE VERSIONS OF THE FEBPM SYSTEM MAY ALSO CONTAIN SENSORS CAPABLE OF COMMUNICATING BACK TO THE CONTROLLER TO DELIVER VARIOUS TYPES OF INFORMATION USED FOR SYSTEM OPERATION.STATUS:BASED ON OTHER PRIORITIES WITH IN AMF THE FEBPM PROGRAM WAS TEMPORALLY SLOWED DOWN WHILE FOCUS WAS PLACED ON OTHER PROGRAMS (EXPENSES $8,713). 1089299 0 779412 14460615 1 1 0 0 0 0 0 0 0 0 1 1 0 0 0 1 0 1 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 1 1 1 0 0 1 49 0 1 102 1 1 1 0 0 0 0 0 0 0 0 0 X 4 4 0 0 0 0 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 1 1 CA X PETRINA HARRIS 6617026883 25134 RYE CANYON LOOP SANTA CLARITA CA 91355 ROBERT GREENBERG CHAIRMAN 2.00 X X 0 0 0 RICHARD WAUGH BOARD MEMBER 2.00 X 0 0 0 MARI DANIHEL BOARD MEMBER 2.00 X 0 0 0 ROBERT GUEZURAGA BOARD MEMBER 2.00 X 0 0 0 BRIAN MANN BOARD MEMBER 2.00 X 0 0 0 DAVID HANKIN CEO 55.00 X 429274 0 35323 FARAH BOROOMAND CFO 53.00 X 252562 0 27878 MARK CHAMBERLAIN COO 55.00 X 302615 0 27302 JOHN PETROVICH GENERAL COUNSEL 52.00 X 306786 0 28524 MICHAEL PERRIN VP, QUALITY AND REGULATORY 48.00 X 172289 0 26479 CHARLES BYERS PRINCIPAL SCIENTIST 40.00 X 177866 0 15422 JAMES WOLFE PRINCIPAL DESIGN ENGINEER 41.00 X 175682 0 26803 GLEN GRIFFITH PRINCIPAL RF COMMUNICATIONS ENGINEER 41.00 X 213197 0 24004 EUSEBIU MATEI MIXED SIGNAL DESIGN GROUP MANAGER 40.00 X 184866 0 20015 NEELIMA FIRTH SR DIRECTOR STRATEGIC PLANNING DEVELOPMENT 42.00 X 179512 0 26766 2394649 0 258516 38 0 1 0 MORGAN LEWIS & BOCKIUS LLP 300 S GRAND AVENUE 22ND FLOOR LOS ANGELES CA 90071 LEGAL SERVICES 4264983 OCEAN TOMO LLC 101 MONTGOMERY STREET SUITE 2100 SAN FRANCISCO CA 94104 EXPERT WITNESS SERVICES 326333 GOODWIN PROCTER LLP 620 8TH AVENUE NEW YORK NY 10018 LEGAL SERVICES 140772 MORRISON & FOERSTER LLP PO BOX 742335 LOS ANGELES CA 90074 LEGAL SERVICES 128097 4 101479 101479 RESEARCH GRANT INCOME 900099 1859751 1859751 1859751 2529156 514120 2015036 26010 26010 159133673 622015 156234937 466193 2898736 155822 3054558 3054558 OTHER INCOME 999999 23750 23750 23750 7594704 1885761 514120 5093344 19000 19000 1642499 1137402 505097 7425645 6640824 784821 128525 117760 10765 732213 654294 77919 656378 576507 79871 1636341 1450396 185945 95074 95074 880954 880954 726795 542980 183495 320 1441044 1333261 96868 10915 379781 334687 45094 1082846 886347 154413 42086 202750 145424 57326 42486 28327 13330 829 455323 376029 78729 565 104206 85148 14995 4063 MISCELLANEOUS 100365 76325 24040 EDUCATION & MORALE 75556 55904 18075 1577 EVENT PRODUCTION 74864 74864 17902645 14460615 3306811 135219 3941925 1963816 1334338 1334675 813225 98181 2517153 9688256 309809 414872 8708581 7135530 1758434 1573051 91293276 83205449 10715128 9402551 755813 724245 1300899 228444 114740000 108633540 4042579 1902791 7155208 13316543 11197787 15219334 X 103542213 93414206 103542213 93414206 114740000 108633540 -10307941 179934 0 X 0 1 X 1 1 1 X WALTER REED NATIONAL MILITARY MEDICAL CENTER BETHESDA MD RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1509358 538782 970576 4930131 4387664 542467 2269092 2209084 60008 1573051 LIMITED PARTNERSHIPS 1720551 F BIONESS INC. 2077000 F MEDALLION THERAPEUTICS, INC. 5600000 F MONOLYTHIX, INC. 5000 F 9402551 X PART X, LINE 2: THE FOUNDATION, UNDER THE PROVISIONS OF ASC 740, INCOME TAXES, HAD NO UNCERTAIN TAX POSITIONS REQUIRING ACCRUAL AS OF MARCH 31, 2015 AND 2014. THE FOUNDATION'S TAX RETURNS ARE SUBJECT TO REVIEW AND EXAMINATION BY FEDERAL AND STATE AUTHORITIES. THE FOUNDATION IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS BY TAXING AUTHORITIES FOR YEARS BEFORE 2011 FOR ITS FEDERAL FILING AND FOR YEARS BEFORE 2010 FOR ITS STATE FILINGS. CENTRAL AMERICA AND THE CARIBBEAN 0 0 INVESTMENTS 10436464 CENTRAL AMERICA AND THE CARIBBEAN 0 0 INVESTMENT FEE EXPENDITURES 401315 0 0 0 0 0 0 10837779 0 10837779 1 0 1 1 1 0 PART I, LINE 3: THE ACCRUAL METHOD OF ACCOUNTING IS USED FOR BOTH AMOUNTS REPORTED AS INVESTMENTS AND EXPENDITURES. X X X X 0 0 0 0 0 0 0 1 0 DAVID HANKIN CEO 317274 0 100000 0 12000 0 5199 0 30124 0 464597 0 0 0 FARAH BOROOMAND CFO 202562 0 50000 0 0 0 4381 0 23497 0 280440 0 0 0 MARK CHAMBERLAIN COO 262615 0 40000 0 0 0 5199 0 22103 0 329917 0 0 0 JOHN PETROVICH GENERAL COUNSEL 236786 0 70000 0 0 0 4980 0 23544 0 335310 0 0 0 MICHAEL PERRIN VP, QUALITY AND REGULATORY 150289 0 22000 0 0 0 3267 0 23212 0 198768 0 0 0 CHARLES BYERS PRINCIPAL SCIENTIST 175516 0 2350 0 0 0 3235 0 12187 0 193288 0 0 0 JAMES WOLFE PRINCIPAL DESIGN ENGINEER 170582 0 5100 0 0 0 3610 0 23193 0 202485 0 0 0 GLEN GRIFFITH PRINCIPAL RF COMMUNICATIONS ENGINEER 192797 0 20400 0 0 0 4206 0 19798 0 237201 0 0 0 EUSEBIU MATEI MIXED SIGNAL DESIGN GROUP MANAGER 181866 0 3000 0 0 0 3744 0 16271 0 204881 0 0 0 NEELIMA FIRTH SR DIRECTOR STRATEGIC PLANNING DEVELOPMENT 164512 0 15000 0 0 0 3612 0 23154 0 206278 0 0 0 PART I, LINE 7 BONUS PAYMENTS WERE MADE, BUT ARE BASED ON ACHIEVEMENTS, GOALS, AND ARE APPROVED BY BOARD OF DIRECTORS. MANN BIOMEDICAL PARK LLC ENTITY MORE THAN 35% OWNED BY ALFRED E. MANN, MEMBER 484347 ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH WAS PARTY TO TWO LEASES WITH MANN BIOMEDICAL PARK, LLC FOR THE FOLLOWING FACILITIES: 1) 25133 RYE CANYON LOOP, SANTA CLARITA FOR $1,749 PER MONTH FOR 4/1/14-8/31/14 AND $1,790 PER MONTH FOR 9/1/14-11/17/14, AND 2) 25134 RYE CANYON LOOP, SANTA CLARITA FOR $58,266 PER MONTH FOR 4/1/14-8/31/14 AND $59,634 PER MONTH FOR 9/1/14-11/17/14. 0 FORM 990, PART VI, SECTION A, LINE 6 AMF HAS 1 SOLE MEMBER AND 4 BOARD MEMBERS. FORM 990, PART VI, SECTION A, LINE 7A THE ORGANIZATION SHALL HAVE UP TO FIVE MEMBERS. ALFRED E. MANN (LEAD MEMBER) HAS THE AUTHORITY TO APPOINT HIS SUCCESSOR AS LEAD MEMBER AND TO APPOINT ALL OTHER MEMBERS. FORM 990, PART VI, SECTION A, LINE 7B THE LEAD MEMBER HAS THE POWER AND RIGHT TO DESIGNATE ALL DIRECTORS. DIRECTORS MAY ONLY BE REMOVED BY THE DIRECTORS WITH WRITTEN CONSENT OF THE LEAD MEMBER. FORM 990, PART VI, SECTION B, LINE 11 A DRAFT OF FORM 990 WAS PRESENTED BY MANAGEMENT TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS FOR THEIR REVIEW AND DISCUSSION. A FULL COPY OF THE FORM WAS PROVIDED TO ALL VOTING MEMBERS PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST DISCLOSURES ARE UPDATED ANNUALLY AND POTENTIAL CONFLICTS ARE REVIEWED PRIOR TO PARTICIPATING IN TRANSACTIONS. IF A CONFLICT EXISTS, THE PERSON WITH A CONFLICT DOES NOT VOTE. THERE HAVE BEEN NO INCIDENCES THIS REPORTING YEAR. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD OF DIRECTORS REVIEWS AND APPROVES THE COMPENSATION OF THE CEO AND HIS DIRECT REPORTS INCLUDING THE CFO. THEY ALSO REVIEW AND APPROVE THE OVERALL ANNUAL ADJUSTMENTS TO COMPENSATION OF OTHER EMPLOYEES. SPECIFIC ADJUSTMENTS FOR OTHER EMPLOYEES ARE HANDLED BY THE CEO AND HEAD OF HUMAN RESOURCES USING COMPARISONS TO SALARY SURVEYS FOR SIMILAR POSITIONS AND EXPERIENCE. DURING THE YEAR ENDED MARCH 31, 2015, THE ORGANIZATION HAD AN OUTSIDE COMPENSATION ANALYSIS COMPLETED COVERING EXECUTIVE MANAGEMENT, KEY EMPLOYEES AND HIGHLY COMPENSATED EMPLOYEES. THE BOARD OF DIRECTORS APPROVED COMPENSATION FOR THE CEO AND HIS DIRECT REPORTS INCLUDING THE CFO. THIS PROCESS WAS DOCUMENTED. FORM 990, PART VI, SECTION C, LINE 19 MEMBERS OF THE PUBLIC OR INTERESTED PARTIES MAY REQUEST TO REVIEW OR RECIEVE A COPY OF THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS BY PHONE OR MAIL. MANN BIOMEDICAL PARK LLC 25141 RYE CANYON LOOP VALENCIA CA 91355 PROPERTY RENTAL CA N/A N/A 0 0 INCUMED LLC 25134 RYE CANYON LOOP 300 VALENCIA CA 91355 HOLDING COMPANY PROVIDING STRATEGIC , OPERATIONAL & CA N/A N/A 0 0 PERQFLO LLC 25134 RYE CANYON LOOP 300 VALENCIA CA 91355 PUMP DEVELOPMENT COMPANY CA N/A N/A 0 0 CORE MANUFACTURING LLC 26432 OAKDALE CANYON LANE CANYON COUNTRY CA 91387 MANUFACTURING & RESEARCH CA N/A UNRELATED 1016413 0 0 0.29840 BIONESS INC 25103 RYE CANYON LOOP VALENCIA CA 91355 DESIGN MANUFACTURE & SALE OF MEDICAL DEVICES DE N/A C 0.03950 0 AXONICS MODULATION TECHNOLOGIES INC 7575 IRVINE CENTER DRIVE SUITE 200 IRVINE CA 92618 454744083 DEVELOPMENT AND COMMERCIALIZATION OF MEDICAL DEVICE (SPINAL CORD STIMULATOR) DE N/A C 0.44150 0 MONOLYTHIX INC 4720 CALLE CARGA CAMARILLO CA 93012 464616473 MONOLITHIC STRUCTURE DEVELOPMENT FOR DISEASE DETECTION, BLOOD ANALYSIS NV ALRED E MANN FOUNDATION FOR SCIENTIFIC RESEARCH C 0.60980 1 MEDALLION THERAPEUTICS INC 28575 LIVINGSTON AVENUE VALENCIA CA 91355 464651082 DEVELOPMENT AND COMMERCIALIZATION OF MEDICAL DEVICE (IMPLANTABLE DRUG PUMP) DE ALRED E MANN FOUNDATION FOR SCIENTIFIC RESEARCH C 0.91400 1 1 0 0 1 0 0 1 0 0 1 1 0 0 1 1 1 1 0 0 MONOLYTHIX INC J 29440 FAIR VALUE OF LEASED SPACE MEDALLION THERAPEUTICS INC D 5665921 CASH MEDALLION THERAPEUTICS INC G 606983 FAIR VALUE OF ASSETS MONOLYTHIX INC A 105182 INTEREST INCOME MEDALLION THERAPEUTICS INC A 408938 INTEREST INCOME MEDALLION THERAPEUTICS INC J 2435 FAIR VALUE OF LEASED SPACE MONOLYTHIX INC D 1505182 CASH